Long Covid is a debilitating condition observed in a subset of recovering Covid-19 patients, that persists after the normal convalescence period. It is characterised by a wide range of symptoms that resemble the post-viral fatigue syndromes that have been observed with other viral diseases e.g. Epstein-Barr virus and also observed in ME/CFS. These symptoms include post-exertional malaise, extremely debilitating fatigue, total body pain, cognitive dysfunction, headaches, nerve pain and tingling and generalised weakness.
A recent study reported that SARS-CoV-2 viral proteins interact with 105 genes involved in bioenergetics and 55 mitochondrial proteins including subunits of the mitochondrial ribosomes, electron transport chain, and proteins regulating mitochondrial biogenesis (Gordon et al, 2020). We are exploring the use of SB200 as a metabolic and mito-protective therapeutic intervention that could relieve the symptoms of Long Covid patients.